MedTrace Logo

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

NCT03090516 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-08-07

No results posted yet for this study

Summary

This project explores Ginkgo biloba ester dispersible tablets influence on cognitive function in patients with mild-to-moderate elderly, to observe the effects of different intervention time on cognitive function, for alzheimer's patients in drug rehabilitation treatment provides an effective solution.

Conditions

Interventions

DRUG

Ginkgo biloba dispersible tablets

Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.

DRUG

Donepezil

Arm A：Aricept 5mg/day

DRUG

Ginkgo biloba dispersible tablets and Donepezil

Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Ting Wu · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-10
Primary Completion
2020-03-10
Completion
2020-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090516 on ClinicalTrials.gov